Medpace Holdings, Inc. (MEDP) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Medpace Holdings, Inc. (MEDP) stock forecast summary
On Oct. 14, 2026, MEDP is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
Medpace Holdings, Inc. is a large-cap company with a market capitalization of $17.02B. It ranks number 3 by market capitalization among the 12 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its P/B Ratio of 39.24x is the highest of the 8 peers that report one. Its ROE of 113.3% is the highest of the 10 peers that report one.
A per-ticker accuracy statistic for MEDP is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, MEDP included.
Follow MEDP freeMEDP price chart and AI forecast
How MEDP ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Medpace Holdings, Inc. (MEDP) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | MEDP | Rank |
|---|---|---|
| Market Cap | $17.02B | 3/12 |
| P/E Ratio | 34.63x | – |
| P/B Ratio | 39.24x | 1/8 |
| EPS | $17.04 | – |
| Book Value/Share | $15.54 | – |
| Revenue/Share | $99.68 | – |
| FCF/Share | $25.32 | – |
Profitability & Margins
| Metric | MEDP | Rank |
|---|---|---|
| ROE | 113.3% | 1/10 |
| ROA | 23.9% | 1/13 |
| ROIC | 93.8% | 1/12 |
| Operating Margin | 21.0% | 2/13 |
| Net Margin | 17.7% | 2/11 |
| EBT Margin | 21.5% | 2/13 |
| Tax Rate | 17.9% | – |
Financial Health
| Metric | MEDP | Rank |
|---|---|---|
| Current Ratio | 0.73x | 10/16 |
| D/E Ratio | 3.74x | 3/11 |
| Financial Leverage | 4.74x | 3/11 |
| Interest Coverage | 733.2x | 1/13 |
| Working Capital | -$385M | 14/15 |
Cash Flow
| Metric | MEDP | Rank |
|---|---|---|
| Operating Cash Flow | $753M | 4/15 |
| Free Cash Flow | $707M | 2/7 |
| Capital Spending | -$46M | 5/7 |
| OCF Growth YoY | 22.6% | 2/5 |
| FCF Growth YoY | 21.9% | – |
| FCF/Sales | 25.4% | 1/8 |
| CapEx/Sales | 1.6% | 6/8 |
Operational Efficiency
| Metric | MEDP | Rank |
|---|---|---|
| Asset Turnover | 1.35x | 1/9 |
| Receivables Turnover | 6.6x | 3/7 |
| Fixed Assets Turnover | 17.7x | 3/9 |
| Days Sales Outstanding | 55 days | 5/7 |
Income Statement
| Metric | MEDP | Rank |
|---|---|---|
| Total Revenue | $2.78B | 4/8 |
| Operating Income | $583M | 4/15 |
| Net Income | $491M | 3/13 |
| SG&A Expense | $189M | 5/12 |
Dividend & Shareholder Information
| Metric | MEDP | Rank |
|---|---|---|
| Shares Outstanding | 28M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $1.05B | 51.1% of assets |
| Cash & Short-term Investments | $503M | 24.4% of assets |
| Accounts Receivable | $421M | 20.4% of assets |
| Total Liabilities | $1.62B | 78.9% of assets |
| Short-term Debt | $1.40B | 68.0% of assets |
MEDP quarterly financials and insider trading
Medpace Holdings, Inc. (MEDP) industry peers
Companies classified under the same SEC industry code as Medpace Holdings, Inc. (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| MEDP Medpace Holdings, Inc. | ▶ | $17.02B |
| IQV Iqvia Holdings Inc. | ▼ | $43.51B |
| INCY Incyte Corp | ▼ | $21.70B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.27B |
| ICLR Icon Plc | ▶ | $12.68B |
| ABSI Absci Corp | ▲ | $1.56B |
| OABI Omniab, Inc. | ▲ | $683M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $100M |
| ONMD Onemednet Corp | ▶ | $24M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BUDZ Weed, Inc. | ▶ | $3M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | N/A |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
| FOXO Foxo Technologies Inc. | ▼ | N/A |
| ISPC Ispecimen Inc. | ▼ | N/A |
Where MEDP sits on the market map
Medpace Holdings, Inc. (MEDP) stock news
Loading...
Medpace Holdings, Inc. (MEDP) stock forecast FAQ
What is the Medpace Holdings, Inc. (MEDP) stock forecast?
On Oct. 14, 2026, MEDP is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
How accurate are Medpace Holdings, Inc. stock predictions?
A per-ticker accuracy statistic for MEDP is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Medpace Holdings, Inc. forecasts updated?
Medpace Holdings, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Medpace Holdings, Inc.'s industry peers?
16 issuers in our coverage, MEDP included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Incyte Corp (INCY), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI), Omniab, Inc. (OABI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.